

information system for managing the human resources, facilities, equipment and supplies. The pharmacy division includes worxa drug therapy management system and worxa universal. The customers of the group are research institutions such as university of California medical center, university of Kansas medical center and hospitals.

Primary SIC and add'l.: 3845 7379 7373

CIK No: 0000874733

Subsidiaries: Digimedics Corp., Informedics Inc., Jac Computer Services Ltd., Mediware Blood Management LLC, Mediware Clinical Management LLC, Mediware Medication Management LLC

Officers: Robert C. Weber/38/Sr. VP, Chief Legal Officer, General Counsel, Sec./\$210,004.00, Mark B. Williams/39/CFO, Principal Accounting Officer/\$189,135.00, John Damgaard/40/COO, Sr. VP/\$225,173.00, Thomas K. Mann/CEO/\$296,308.00

Directors: Lawrence Auriana/65/Chmn., John Gorman/Dir., Ira Nordlicht/Dir., Roger Clark/75/Dir., Robert F. Sanville/66/Dir., Joseph Delario/76/Dir., Richard Greco/40/Dir.

Owners: Mark Williams/1.40%, Richard Greco, Ira Nordlicht, John Gorman/1.00%, Insiders/37.60%, Peninsula Capital Management, Inc./9.50%, Constellation Software Inc./13.80%, Kelly T. Mann/1.80%, James F. Burgess, Lawrence Auriana/31.70%, Robert Tysall-Blay, Camnell Capital/9.90%, Rob Weber/1.50%, Bank of America Corporation/5.50%, Robert Sanville, Phil Coelho, Roger Clark, Bares Capital Management/9.60%, John Damgaard/1.20%

Financial Data: Fiscal Year End:06/30 Latest Annual Data: 6/30/2008

Year	Sales	Net Income
2008	\$39,437,000	\$728,000
2007	\$41,192,000	\$2,326,000
Curr. Assets:	\$31,464,000	Curr. Liab.: \$12,469,000
Plant, Equip.:	\$1,831,000	Total Liab.: \$17,737,000
Total Assets:	\$57,628,000	Net Worth: \$39,891,000

P/E Ratio: 76.67
Indic. Yr. Divd.: NA
Debt/Equity: 0.0000

Medizone International Inc.

PO Box 742, Stinson Beach, CA, 94970; **PH:** 1-415-868-0300; **http://** www.medizoneint.com;

Email: Operations@MedizoneInt.com

General - Incorporation.....NV **Stock** - Price on:12/31/2008\$0.25

Employees1 Stock Exchange.....OTC
AuditorHJ Associates & Consultants LLP Ticker Symbol.....MZEI
Stk Agt.....Colonial Stock Transfer Co Inc Outstanding Shares195,590,000
Counsel.....NA E.P.S.....\$0.00
DUNS No.....NA Shareholders.....3,500

Business: The group's principal activity is to develop, promote and distribute ozone-generating equipment and related products for medical applications. The product of the group includes drug Medizone that can be used as a therapeutic drug in humans to inactivate certain viruses and to treat certain viral diseases including aids-related virus, hepatitis b, hepatitis c, epstein-barr, herpes, cytomegalovirus and to decontaminate blood and blood products. The group operates from the United States.

Primary SIC and add'l.: 2834

CIK No: 0000753772

Subsidiaries: Medizone Canada Ltd., Medizone International Inc.

Officers: Edwin G. Marshall/65/Chmn., CEO/\$170,000.00, Steve M. Hanni/40/CFO

Directors: Edwin G. Marshall/65/Chmn., CEO, Richard G. Solomon/65/Dir., Daniel Hoyt/68/Dir.

Financial Data: Fiscal Year End:12/31 Latest Annual Data: 12/31/2007

Year	Sales	Net Income
2007	NA	-\$552,000
2006	NA	-\$356,000
2005	NA	-\$326,000
Curr. Assets:	NA	Curr. Liab.: \$3,640,000
Plant, Equip.:	NA	Total Liab.: \$3,865,000
Total Assets:	NA	Net Worth: -\$3,865,000

Indic. Yr. Divd.: NA
Debt/Equity: 0.0000

MedLink International Inc.

11 Oval Dr., Ste. 200B, Islandia, NY, 11749; **PH:** 1-631-342-8800; **Fax:** 1-631-342-8819;

http:// www.medlinkus.com; **Email:** info@medlinkus.com

General - Incorporation.....DE **Stock** - Price on:12/31/2008\$1

Employees24 Stock Exchange.....OTC
AuditorFarber, Blicht, Eyerman & Herzog Ticker Symbol.....MLKNA
Stk Agt.....Computershare Trust Co. Outstanding Shares31,370,000
Counsel.....NA E.P.S.....-\$0.11
DUNS No.....NA Shareholders.....1,019

Business: The group's principal activities include selling, implementing and supporting software solutions and hardware to healthcare providers for secure access to clinical, administrative and financial data in real time. Specific customers of the group include New Island Hospital, UCLA, Miracle Mile Medical Center and select radiology groups. The group operates from the United States.

Primary SIC and add'l.: 7374 7389 7373 7371 7372 8099

CIK No: 0000225501

Subsidiaries: Krad Consulting LLC, Medlink Fe Inc., Medlink India Software Ltd., Medlink Usa Inc., Medlink Vpn Inc., Norika Usa Inc., Western Media Acquisition Corp., Western Media Publishing Corp.

Officers: Ray Vuono/Chmn., CEO, Pres./\$10,725.00, Jameson Rose/CFO, Exec. VP/\$10,725.00, Konrad Kim/Dir., CTO/\$10,725.00, James Decker/44/Exec. VP - Sales

Directors: Ray Vuono/Chmn., CEO, Pres., Konrad Kim/Dir., CTO, Michael Carvo/Dir.

Owners: Insiders/49.44%, Konrad Kim/5.39%, Jameson Rose/17.17%, Jerry Bermensolo/14.20%, Michael Carvo/1.82%, Ray Vuono/25.06%

Financial Data: Fiscal Year End:12/31 Latest Annual Data: 12/31/2007

Year	Sales	Net Income
2007	\$280,000	-\$2,463,000
2006	\$11,000	-\$1,589,000
2005	NA	-\$957,000
Curr. Assets:	\$42,000	Curr. Liab.: \$1,655,000
Plant, Equip.:	\$134,000	Total Liab.: \$1,658,000
Total Assets:	\$1,210,000	Net Worth: -\$448,000

Indic. Yr. Divd.: NA
Debt/Equity: -0.0100

Medtox Scientific Inc.

402 W County Rd. D, St. Paul, MN, 55112; **PH:** 1-651-636-7466; **Fax:** 1-651-636-5351;

http:// www.medtox.com; **Email:** investors@medtox.com

General - IncorporationDE **Stock** - Price on:12/31/2008\$7.81
Employees523 Stock Exchange.....NDQ
AuditorDeloitte & Touche LLP Ticker Symbol.....MTOX
Stk Agt.....American Stock Transfer & Trust Outstanding Shares8,460,000
Counsel.....Fredrikson & Byron E.P.S.....\$0.74
DUNS No.....NA Shareholders.....874

Business: The group's principal activities are to manufacture and distribute diagnostic devices and forensic and clinical laboratory services. The group operates through two subsidiaries, medtox laboratories, inc. And medtox diagnostics, inc. The group's laboratory provides services like forensic toxicology, clinical toxicology and heavy metal analyses. It also provides logistics, data management and program management services. The group's diagnostics segment develops, manufactures and markets products based on immunoassay technology for the detection of antibiotic residues, mycotoxins, drugs of abuse and other hazardous substances. It also distributes agridiagnostic and food safety testing products. The group's products and services include profile-ii test system, for detection of drugs of abuse in human urine, ez-screen breath control alcohol test system and verdict-ii on site screening devices.

Primary SIC and add'l.: 2836 8071

CIK No: 0000739944

Subsidiaries: Medtox Diagnostics Inc., Medtox Laboratories Inc., New Brighton Business Center LLC

Officers: James A. Schoonover/CMO, VP - Sales, Marketing/\$207,200.00, Kevin J. Wiersma/CFO, COO, VP - Laboratory Division/\$205,066.00, Richard J. Braun/Chmn., CEO, Pres./\$336,903.00, Susan E. Puskas/VP - Quality, Regulatory Affairs, Human Resources/\$205,066.00, Mitchell B. Owens/COO, VP, Diagnostics Division/\$193,873.00, Jennifer A. Collins/Dir. - Forensic Laboratory, Karla J. Walker/Dir. - Clinical Toxicology

Directors: Richard J. Braun/Chmn., CEO, Pres., Brian P. Johnson/Dir., Samuel C. Powell/Dir., Robert A. Rudell/Dir., Robert J. Marzec/Dir.

Owners: Samuel C. Powell/3.46%, Kevin J. Wiersma/1.84%, Susan E. Puskas/1.56%, Renaissance Technologies LLC/6.24%, Robert A. Rudell, James A. Schoonover/2.00%, Brian P. Johnson, Mitchell B. Owens/2.30%, Fidelity Management & Research Co./7.95%, Insiders/16.11%, Richard J. Braun/4.50%, Robert J. Marzec

Financial Data: Fiscal Year End:12/31 Latest Annual Data: 12/31/2007

Year	Sales	Net Income
2007	\$80,285,000	\$6,690,000
2006	\$69,804,000	\$4,548,000
2005	\$63,047,000	\$3,318,000
Curr. Assets:	\$22,883,000	Curr. Liab.: \$11,634,000
Plant, Equip.:	\$26,885,000	Total Liab.: \$14,293,000
Total Assets:	\$69,949,000	Net Worth: \$55,656,000

P/E Ratio: 10.55
Indic. Yr. Divd.: NA
Debt/Equity: 0.0100

Medtronic Inc.

710 Medtronic Pkwy., Minneapolis, MN, 55432; **PH:** 1-763-514-4000; **Fax:** 1-763-514-4879;

http:// www.medtronic.com

General - IncorporationMN **Stock** - Price on:12/31/2008\$31.39
Employees40,351 Stock Exchange.....NYSE
AuditorPricewaterhousecoopers LLP Ticker Symbol.....MDT
Stk Agt.....Wells Fargo Shareowner Services Outstanding SharesNA
Counsel.....NA E.P.S.....\$1.95
DUNS No.....NA Shareholders.....53,600

Business: The group's principal activity is to manufacture implantable biomedical devices. The group's products include catheters, stents, valves, and surgical ablation technologies. In the year 2007, the group acquired Kyphon Inc. The group operates from the United States.

Primary SIC and add'l.: 3845

CIK No: 0000064670

Subsidiaries: 160 Subsidiaries included in the Index

Officers: Stephen H. Mahle/Exec. VP, Sr. Healthcare Policy Advisor/\$620,000.00, James H. Dallas/Sr. VP - Quality, Operations, Richard E. Kuntz/Sr. VP, Pres. - Neuromodulation, Peter L. Wehrly/Sr. VP, Pres. - Spinal, Biologics, Pat MacKin/Sr. VP, Pres. - Cardiac Rhythm Disease Management, Christopher J. O'Connell/Sr. VP, Pres. - Diabetes, Bill Hawkins/CEO, Pres., Dan Lemaitre/Sr. VP, Corporate Strategy and Development, Martha Goldberg Aronson/Sr. VP, Chief Talent Officer, Bob Blankemeyer/VP, Pres. - Surgical Technologies, Kathy Erickson Digiorno/VP, Chief Ethics, Compliance Officer, Stephen La Neve/Sr. VP, Pres. - Spinal, Biologics, Catherine Szyman/Sr. VP - Strategy, Innovation, Kathleen Erickson Digiorno/VP, Chief Ethics, Compliance Officer, Jean-Luc Butel/Sr. VP, Pres. - International/\$440,000.00, Susan Alpert/Sr. VP, Chief Regulatory Officer, William A. Hawkins/55/Dir., COO, Pres./\$996,000.00, Terrance L. Carlson/Sr. VP, General Counsel, Corp. Sec., Barry W. Wilson/65/Sr. VP - International Affairs, Oern R. Stuge/55/Sr. VP, Pres. - Europe, Canada, Latin America, Emerging Markets, Gary L. Ellis/CFO, Sr. VP/\$600,000.00, Stephen N. Oesterle/Sr. VP - Medicine, Technology, Scott R. Ward/Sr. VP, Pres. - Cardiovascular, Michael F. Demane/53/COO

Directors: Arthur D. Collins/61/Chmn., Jean-Pierre Rosso/Dir., David L. Calhoun/Dir., James T. Lenehan/Dir., Kendall J. Powell/Dir., Victor J. Dzau/Dir., Denise M. O'Leary/Dir., William A. Hawkins/55/Dir., COO, Pres., Robert C. Pozen/Dir., Jack W. Schuler/Dir., Shirley Ann Jackson/Dir., Richard H. Anderson/Dir.

Owners: Denise M. O'Leary, Stephen H. Mahle, James T. Lenehan, Insiders, Jean-Luc Butel, Richard H. Anderson, Gary L. Ellis, Kendall J. Powell, William A. Hawkins, Capital World Investors/5.50%, Robert C. Pozen, Michael F. DeMane, Jack W. Schuler, Jean-Pierre Rosso, David L. Calhoun, Arthur D. Collins, Shirley Ann Jackson, Victor J. Dzau

Financial Data: Fiscal Year End:04/28 Latest Annual Data: 4/25/2008

Year	Sales	Net Income
2008	\$13,515,000,000	\$2,231,000,000
2007	\$12,299,000,000	\$2,802,000,000
2006	\$11,292,000,000	\$2,546,700,000
Curr. Assets:	\$10,376,600,000	Curr. Liab.: \$4,405,800,000
Plant, Equip.:	\$1,881,100,000	Total Liab.: \$10,282,300,000
Total Assets:	\$19,664,800,000	Net Worth: \$9,382,500,000

P/E Ratio: 16.10
Indic. Yr. Divd.: \$0.500
Debt/Equity: 0.4400